{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:12:01Z","timestamp":1785017521323,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1745,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K23 HL146887-02"],"award-info":[{"award-number":["5K23 HL146887-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K23 HL146887\u201002"],"award-info":[{"award-number":["5K23 HL146887\u201002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We sought to compare the generalizability and prognostic implications of heart failure with preserved ejection fraction (HFpEF) scores (HFA-PEFF and H2FPEF score) in Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) and Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial participants and matched controls from the Atherosclerosis Risk in Community (ARIC) study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Based on the respective scores, the study participants from the TOPCAT (N = 356), RELAX (N = 216), and ARIC (N = 379) studies were categorized as having a low, intermediate, or high likelihood of HFpEF. Age, sex, and race matched controls free of cardiovascular disease who had unexplained dyspnoea were used to evaluate the diagnostic performance. The prognostic value of scores was assessed using multivariable-adjusted Cox regression analyses. The median HFA-PEFF scores in the TOPCAT, RELAX, and ARIC studies were 5.0 [interquartile range (IQR): 5.0\u20136.0], 4.0 (IQR: 2.0\u20134.0), and 3.0 (IQR: 2.0\u20134.0), respectively. The median H2FPEF scores in the three studies were 5.5 (IQR: 4.0\u20137.0), 6.0 (IQR: 4.0\u20137.0), and 3.0 (IQR: 2.0\u20135.0), respectively. A low HFA-PEFF and H2FPEF score can rule out HFpEF with high sensitivity (99.5% and 99.6%, respectively) and negative predictive value (95.7% and 98.3%, respectively). A high HFA-PEFF and H2FPEF score can rule-in HFpEF with good specificity (82.8% and 95.6%, respectively) and positive predictive value (79.9% and 90.4%, respectively). Among TOPCAT participants, the hazard for adverse cardiovascular events per point increase in HFA-PEFF and H2FPEF score was 1.26 (95% confidence interval: 0.98\u20131.63) and 1.01 (95% confidence interval: 0.88\u20131.15), respectively. A higher H2FPEF score was associated with lower peak oxygen intake in RELAX trial participants (adjusted P = 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HFA-PEFF and the H2FPEF scores are reliable diagnostic tools for HFpEF. The prognostic utility of HFpEF scores requires further validation in larger rigorously phenotyped populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13288","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T22:20:45Z","timestamp":1615501245000},"page":"2089-2102","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Diagnostic and Prognostic Implications of Heart Failure with Preserved Ejection Fraction Scoring Systems"],"prefix":"10.1093","volume":"8","author":[{"given":"Vibhu","family":"Parcha","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargya","family":"Malla","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kalra","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, University of Minnesota , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanders-van Wijk","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre (MUMC+) , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]},{"name":"Section of Cardiology, Birmingham Veterans Affairs Medical Center , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"2026012114240608100_ehf213288-bib-0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012114240608100_ehf213288-bib-0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0003","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026012114240608100_ehf213288-bib-0004","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ehjci\/jex067","article-title":"Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study","volume":"18","author":"Lancellotti","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114240608100_ehf213288-bib-0005","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114240608100_ehf213288-bib-0006","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h910","article-title":"The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting","volume":"350","author":"Roberts","year":"2015","journal-title":"BMJ"},{"key":"2026012114240608100_ehf213288-bib-0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0008","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0009","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114240608100_ehf213288-bib-0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ejhf.1614","article-title":"Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction","volume":"22","author":"Barandiaran Aizpurua","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0011","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ajh\/hpz108","article-title":"H2FPEF score as a prognostic value in HFpEF patients","volume":"32","author":"Sueta","year":"2019","journal-title":"Am J Hypertens"},{"key":"2026012114240608100_ehf213288-bib-0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114240608100_ehf213288-bib-0013","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"2026012114240608100_ehf213288-bib-0014","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","article-title":"PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design","volume":"5","author":"Redfield","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.aje.a115184","article-title":"The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives","volume":"129","author":"The ARIC investigators","year":"1989","journal-title":"Am J Epidemiol"},{"key":"2026012114240608100_ehf213288-bib-0016","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/ejhf.1542","article-title":"Application of the H2FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial","volume":"21","author":"Myhre","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0017","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.118.039051","article-title":"Implications of the H2FPEF score in a cohort of patients with heart failure with preserved ejection fraction","volume":"139","author":"Segar","year":"2019","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0019","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114240608100_ehf213288-bib-0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12265-017-9756-y","article-title":"Precision medicine for heart failure with preserved ejection fraction: an overview","volume":"10","author":"Shah","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"2026012114240608100_ehf213288-bib-0021","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.amjcard.2020.03.006","article-title":"Clinical, demographic, and imaging correlates of anemia in heart failure with preserved ejection fraction (from the RELAX trial)","volume":"125","author":"Parcha","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026012114240608100_ehf213288-bib-0022","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1253\/circj.CJ-19-0699","article-title":"H2FPEF score for the prediction of exercise intolerance and abnormal hemodynamics in japanese\u2014evaluation by exercise stress echocardiography combined with cardiopulmonary exercise testing","volume":"83","author":"Takahari","year":"2019","journal-title":"Circ J"},{"key":"2026012114240608100_ehf213288-bib-0023","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0024","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.mayocp.2018.11.037","article-title":"Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study","volume":"94","author":"Reddy","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026012114240608100_ehf213288-bib-0025","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/jch.13743","article-title":"Hypertension, diastolic stress test, and HFpEF: does new scoring system change something?","volume":"21","author":"Tadic","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026012114240608100_ehf213288-bib-0026","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2018.06.008","article-title":"Heart failure with preserved ejection fraction expert panel report: current controversies and implications for clinical trials","volume":"6","author":"Parikh","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0027","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026012114240608100_ehf213288-bib-0028","article-title":"Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114240608100_ehf213288-bib-0029","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jcmg.2017.10.008","article-title":"Comparison of the diastolic stress test with a combined resting echocardiography and biomarker approach to patients with exertional dyspnea: diagnostic and prognostic implications","volume":"12","author":"Kosmala","year":"2019","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/3\/2089\/65797843\/eschf_8_3_2089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/3\/2089\/65797843\/eschf_8_3_2089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:30:08Z","timestamp":1769023808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/3\/2089\/8363439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,11]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13288","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6]]},"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"2020-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}